Valuation: Merck & Co., Inc.

Capitalization 294B 249B 229B 217B 402B 27,213B 409B 2,685B 1,053B 13,191B 1,103B 1,080B 46,492B P/E ratio 2026 *
28.2x
P/E ratio 2027 * 13.6x
Enterprise value 327B 277B 255B 241B 446B 30,215B 454B 2,981B 1,169B 14,647B 1,225B 1,199B 51,622B EV / Sales 2026 *
4.9x
EV / Sales 2027 * 4.48x
Free-Float
70.67%
Yield 2026 *
2.84%
Yield 2027 * 2.93%
1 day+3.13%
1 week-1.94%
Current month-1.01%
1 month+2.76%
3 months+9.41%
6 months+40.43%
Current year+13.12%
1 week 114.71
Extreme 114.71
121.3
1 month 112.72
Extreme 112.72
124
Current year 104.43
Extreme 104.43
125.14
1 year 73.31
Extreme 73.31
125.14
3 years 73.31
Extreme 73.31
134.63
5 years 70.89
Extreme 70.89
134.63
10 years 52.83
Extreme 52.83
134.63
Manager TitleAgeSince
Chief Executive Officer 59 2021-06-30
Director of Finance/CFO 57 2021-03-31
Chief Tech/Sci/R&D Officer 57 2020-07-31
Director TitleAgeSince
Director/Board Member 65 2007-11-26
Director/Board Member 73 1995-08-31
Chairman 59 2022-11-30
Change 5d. change 1-year change 3-years change Capi.($)
+3.13%-1.94%+52.65%+3.53% 294B
+2.55%-1.32%+10.37%+148.97% 830B
-0.15%-1.79%+48.71%+41.35% 564B
-0.29%+0.21%+20.46%+29.28% 369B
+2.07%+1.39%+25.20%+15.13% 328B
+1.72%-0.74%+49.33%+27.86% 318B
+1.19%-2.41%+31.10%+34.87% 291B
+1.69%+1.22%+28.13%+43.23% 192B
+1.24%+8.21%-38.18%-55.23% 182B
-0.66%-0.97%+31.66%+64.58% 171B
Average +1.25%+0.03%+25.94%+35.36% 353.84B
Weighted average by Cap. +1.37%-0.64%+27.11%+54.24%

Financials

2026 *2027 *
Net sales 66.66B 56.47B 51.96B 49.17B 91.13B 6,168B 92.74B 609B 239B 2,990B 250B 245B 10,539B 70.31B 59.56B 54.8B 51.86B 96.12B 6,506B 97.81B 642B 252B 3,154B 264B 258B 11,115B
Net income 10.53B 8.92B 8.21B 7.77B 14.4B 975B 14.65B 96.16B 37.7B 472B 39.51B 38.69B 1,665B 21.42B 18.14B 16.69B 15.8B 29.28B 1,982B 29.8B 196B 76.66B 961B 80.34B 78.67B 3,386B
Net Debt 32.45B 27.49B 25.29B 23.94B 44.36B 3,002B 45.14B 296B 116B 1,455B 122B 119B 5,130B 21.2B 17.96B 16.52B 15.64B 28.98B 1,962B 29.49B 194B 75.88B 951B 79.52B 77.87B 3,351B
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).
Employees
74,000
Date Price Change Volume
26-04-17 119.07 $ +3.13% 16,194,901
26-04-16 115.46 $ -2.07% 11,399,886
26-04-15 117.90 $ -1.72% 7,689,371
26-04-14 119.96 $ -0.16% 12,449,439
26-04-13 120.15 $ -1.05% 6,357,339
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
119.07USD
Average target price
129.81USD
Spread / Average Target
+9.02%

Quarterly revenue - Rate of surprise